Swiss pharmaceutical company Roche has announced that a new antibiotic, zosurabalpin, is progressing to phase 3 testing.

Swiss drugmaker Roche said on Monday it would advance testing of an antibiotic against a common drug-resistant bacteria that ...

Roche is planning to move a new antibiotic into late-stage clinical trials after studies showed it had potential to tackle a ...

Roche (RHHBY) is planning to move a new antibiotic into late stage clinical trials after early studies showed it had ...

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...

Roche is moving its novel antibiotic zosurabalpin into phase 3 testing for carbapenem-resistant Acinetobacter baumannii (CRAB), a 'superbug' that is considered an 'urgent threat' by the CDC, in what ...

Australia’s second-largest private hospital operator, Healthscope, is in receivership with ten non-binding offers for ...

The phase 3 IMforte study randomised adults with extensive-stage SCLC to receive Roche’s PD-L1 inhibitor Tecentriq ...

A group of advisers to the Food and Drug Administration said Roche Holding AG needs to study its blood cancer treatment in ...

FRANKFURT — Swiss drugmaker Roche (ROG.S), said on Monday it would advance testing of an antibiotic against a common drug-resistant bacteria that causes serious hospital infections into the ...

If successful, it would be the first new class of drug against certain bacteria strains for more than 50 years ...